

Curing Patients with Resistant TB

Infectious Diseases and Vaccines

After HIV/AIDS, tuberculosis is still the greatest killer among the infectious diseases. A research team in Belgium, led by Koen Andries, has discovered a new medicine for MDR-TB (multidrug-resistant tuberculosis). According to the Bill & Melinda Gates Foundation, this is the first tuberculosis medicine with a new mechanism of action in decades. MDR-TB is a complex form of tuberculosis caused by bacteria that are resistant to the standard first-line TB treatment. Janssen is working together with its partners around the world to improve access to medicines and care for TB patients.

OUR EFFORTS

NEW MEDICINE FOR MDR-TB

(in the WHO list of essential medicines)

WORKING TOGETHER ON INCREASED ACCESS

TB Medicine

Research INTO IMPROVED DIAGNOSIS AND TREATMENT

9,000,000

PEOPLE WITH TB¹

1,500,000

DEATHS PER YEAR¹

¹In 2013. Global Tuberculosis Report 2014 - WHO

MARCH 2014

EU approval of new medicine.

APRIL 2014

Agreed with the International Dispensary Association to set up the Stop TB Partnership and make medicine available in more than 130 impoverished countries.

MAY 2014

New medicine available for patients in Belgium.

JULY 2014

The research team in Belgium, in collaboration with the Institute of Tropical Medicine in Antwerp, published the results of the discovery of a mechanism of resistance against the TB medicine.

JUNE 2014

Janssen team wins European Inventor Award for the discovery of MDR-TB medicine.

Koen Andries and Jérôme Guillemont receive the award.

AUGUST 2014

Our parent company Johnson & Johnson, and worldwide chairman of Janssen Paul Stoffels, travel to South Africa, which is severely affected by MDR-TB and XDR-TB. Here, they visit several patients and donate a significant amount to the government.

SEPTEMBER 2014

Janssen announces a new collaboration with Harvard Medical School to tackle drug-resistant tuberculosis more efficiently, with a specific focus on children.

DECEMBER 2014

Janssen contributes an estimated \$30 million worth of its anti-MDR-TB treatment. The United States Agency for International Development (USAID) will work with its implementing partners, national TB programs and Janssen to ensure responsible access and appropriate use of the treatment.

JUNE 2015

Janssen receives the prestigious Prix Galien for the development of a new treatment for MDR-TB.

